Mylan Completes Expansion of Vermont Transdermal Patch Facility
Mylan completes expansion of its transdermal patch facility in Vermont.
Mylan has completed an 85,000 ft2, three-story expansion project at its transdermal patch facility in St. Albans, Vermont. The facility, operated by Mylan Technologies Inc. (MTI), is a subsidiary of Mylan that focuses on transdermal drug delivery. Mylan's investment includes expanded R&D capabilities and additional manufacturing and laboratory space. In addition, Mylan is in the process of adding more than 160 new positions to its St. Albans-based workforce.
The 14-month expansion project has increased MTI's total operating space to more than 391,000 ft2.
Source: Mylan
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
